- Trial phase
- Phase 2
- Time to market
- Multiple years away from potential approval. The IBD combination is in Phase 2b with AbbVie evaluating Phase 3 acceleration options, meaning an approved product is likely 5+ years away if development continues successfully. The HIV program faces a more uncertain path given mixed Phase 2 results.
- Why 3/10
- ABBV-382 is a Phase 2 asset in a massive, diversified pipeline at AbbVie (a ~$295B market cap company with $10B+ H1 2026 Skyrizi revenue alone). No imminent dated binary catalyst (PDUFA or pivotal readout) is scheduled in the next ~12 months. The Phase 2a TARGET-CD results were just reported on October 19, 2026, and the next catalyst is the Phase 2b platform study readout has no announced date. Even positive data would move AbbVie shares only modestly given the company's scale.
The next catalyst for ABBV-382 is the ongoing Phase 2b platform basket study (M26-266) evaluating Skyrizi + ABBV-382 in Crohn's disease and ulcerative colitis, which began enrollment in July 2026. No specific readout date has been announced. AbbVie has indicated it is evaluating Phase 3 acceleration options for the IBD combination, so a Phase 3 start announcement could be a positive catalyst. The HIV program's mixed Phase 2 results make further development in that indication uncertain.
Price Chart
Executive Summary
ABBV-382 (trosunilimab) is AbbVie's investigational anti-alpha4beta7 integrin monoclonal antibody being developed in two distinct areas: as part of a functional HIV cure strategy (in combination with budigalimab) and as a next-generation inflammatory bowel disease therapy (combined with Skyrizi as ABBV-466). Phase 2a TARGET-CD results presented October 19, 2026 at UEG Week showed the Skyrizi + ABBV-382 combination achieved 30.2% endoscopic remission at Week 12 versus 21.3% for Skyrizi alone and 18% for ABBV-382 alone, with rates rising to 40.5% by Week 24. In HIV, Phase 2 results from CROI 2026 (February 2026) showed the budigalimab + trosunilimab combination delayed viral rebound in about a quarter of patients after stopping antiretroviral therapy, but did not prevent rebound long-term. Both programs remain in Phase 2, and ABBV-382 is a small part of AbbVie's massive, diversified pipeline.
How It Works
ABBV-382 is a monoclonal antibody (a lab-made protein that acts like a natural antibody) that targets and blocks alpha4beta7 integrin, a protein on the surface of certain immune cells that helps them travel to the gut. By blocking this protein, the drug aims to reduce gut inflammation (in Crohn's disease/ulcerative colitis) and also interfere with HIV's ability to infect cells and hide in the body (for HIV functional cure).
Trial Status
ABBV-382 is in Phase 2 development across two indications. For Crohn's disease, the Phase 2a TARGET-CD trial (NCT06548542, ~300 patients) met its primary endpoint in October 2026, showing the Skyrizi combination (ABBV-466) outperformed both monotherapies. A larger Phase 2b platform basket study (M26-266) began enrolling in July 2026, evaluating the combination in both Crohn's disease and ulcerative colitis. For HIV, a Phase 2 study (NCT06032546, 163 patients randomized across six arms) testing budigalimab + ABBV-382 was completed and results were presented at CROI 2026 in February 2026, showing delayed but not prevented viral rebound after ART interruption.
The Two-Sided Case
Upcoming Catalysts
- Phase 2b platform basket study (M26-266) readout in Crohn's disease and ulcerative colitis - no date announced
- Potential Phase 3 start announcement for Skyrizi + ABBV-382 in IBD
- Further HIV functional cure data updates
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbbVie Inc. 8-K ABBV ·Originating report